MONICA BENAVIDEZ: Open Payments
NPI 1710182225 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$255,238 in 417 payments from 8 companies in 2025. Trend: 2023 $57,827 · 2024 $113,821 · 2025 $255,238
Speaker / faculty: $190,744Travel & lodging: $48,010Food & beverage: $8,598Consulting: $7,886
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 148 | $113,243 |
| E.R. Squibb & Sons, L.L.C. | 135 | $83,940 |
| Alkermes, Inc. | 97 | $57,305 |
| Neurocrine BioSciences, Inc. | 15 | $358 |
| Janssen Pharmaceuticals, Inc | 16 | $262 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
Products named: UZEDY, COBENFY, LYBALVI, ARISTADA, INGREZZA, INVEGA SUSTENNA, AUSTEDO XR, FANAPT.
Industry payments across AZ — which companies pay providers there.
